CERo Therapeutics Holdings, Inc., a cellular immunotherapy company based in South San Francisco, has announced a significant presentation of data from its ongoing Phase 1 clinical trial, known as CERTAIN-T. This trial focuses on the company’s lead compound, CER-1236, and will be highlighted during a late-breaking oral poster session at the Tandem Meeting of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) taking place from February 4 to 6, 2026 in Salt Lake City, Utah.
The presentation will feature interim results from the first cohort of the CERTAIN-T trial, demonstrating a positive safety and tolerability profile for CER-1236. Specifically, the data indicates a remarkable in vivo cell expansion, with a notable increase of approximately 20 to 70-fold, peaking between days 7 and 14 after treatment. Following this initial growth phase, the therapy also exhibited prolonged persistence.
Among the findings, the team will discuss the case of an index patient diagnosed with acute myeloid leukemia (AML), which had progressed from myelodysplastic syndrome (MDS). This patient received a total of four infusions of CER-1236 over five months, starting at the lowest dose level. Prior to the treatment, the patient faced frequent platelet transfusions. Remarkably, after undergoing the CER-1236 infusions, the patient achieved transfusion independence that lasted more than two months, surpassing the commonly accepted durability benchmark of 56 days.
The upcoming presentation at the ASTCT and CIBMTR meeting underscores CERo Therapeutics’ commitment to advancing innovative therapies in the field of cellular immunotherapy. The data reflects the company’s focus on developing new treatment options for patients with challenging hematological conditions, highlighting the potential impact of CER-1236 in clinical practice.
As the trial progresses, CERo Therapeutics aims to gather more comprehensive data to further establish the efficacy of CER-1236. The findings presented at the meeting are expected to contribute to ongoing discussions in the medical community regarding the future of cellular therapies in treating complex blood disorders.